Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practicing in specific cardiology domains.
Dr. Christoph Schukro,
Shock delivery by implantable cardioverter defibrillator (ICD) is a life-saving measure in ventricular tachyarrhythmia. Nevertheless ICD shocks have been related to increased mortality in recent studies, when compared to ICD patients without documented shocks. This review takes a look at this "shock paradox".
Although shock delivery by implantable cardioverter-defibrillators (ICD) is a life-saving measure in cases of ventricular tachyarrhythmia, there have been a few notable effects since it was first discovered in the 80's:
Interestingly, intracardiac shocks during defibrillation threshold (DFT) testing lead to a significant reduction in cardiac index only in patients with a reduced LVEF <30% (6), thus suggesting a loss of systolic function especially in previously damaged myocardium. In 2008, a correlation was found between ICD shocks and mortality, and was labeled the shock paradox in ICD therapy.
Accelerated tachyarrhythmia was associated with significantly higher all-cause mortality: Our own single center analysis on a collective of 1,170 ICD patients over a mean follow-up of 5 years was the first to focus on accelerated ventricular tachyarrhythmia, defined as acceleration (or induction) of a ventricular arrhythmia with a decrease of 10% of the initial cycle length caused by ATP or shock delivery (11). Indeed, in previous publications, the incidence of accelerated ventricular arrhythmias ranged between 1% and 5% within follow-up periods of 2 years maximum. (12-16) Acceleration was documented in 8.5% of all patients and in 17% of patients with documented ATP during this longer follow-up period. Almost all ventricular accelerations were induced by predominantly appropriate ATP (97%) and were in the end, terminated with a shock (99%). Occurrence and recurrence of accelerated tachyarrhythmia were significantly correlated with reduced systolic left ventricular function (LVEF <40%). Most notably, accelerated tachyarrhythmia was associated with significantly higher all-cause mortality. In the multivariable analysis, accelerated ventricular tachyarrhythmia and LVEF <40% were independent predictors for all-cause mortality. In patients with documented ATP, acceleration was an independent mortality predictor as well. Therefore, we found once more a significant correlation between shock delivery and mortality.
However, progressive deterioration of systolic heart failure was likely to be the underlying cause for increased mortality in ICD patients (see next paragraph). The detailed interrelations we found in our collective are summarised in the following figure.Figure: Parameters with influence on all-cause mortality in patients with ICD (provided by author from reference 11).
Patients with stable heart failure NYHA-class I-III revealed local injury currents: A recent investigation on DFT testing in 310 patients with stable heart failure NYHA-class I-III revealed local injury currents (LIC) in the post-shock intracardiac ECG as a clue for pre-damaged myocardium. (17) These LIC are late-potential-like abnormalities of the right ventricular ECG. First, the presence of LIC during DFT testing resulted in a significantly higher adverse event rate (i.e. death, or hospitalisation for deterioration of heart failure). Remarkably, a significant correlation between a higher event rate and the occurrence of ICD shocks was only found in patients with documented LIC. On the other hand, a missing LIC leads to an identical adverse event rate in patients with or without ICD shock.
Thus, local injury currents reflecting a pre-damaged myocardium in patients with progression of systolic heart failure might be the missing link between ICD shock delivery and increased mortality.
The presented "shock paradox" is a chicken-and-egg question in cardiology: can ICD shocks be lethal in the long term, or, are patients with a higher risk of death supposed to undergo shocks?Intracardiac shocks are saving lives in cases of ventricular tachyarrhythmia, but a significant correlation between shocks and mortality was reported in several studies on ICD therapy. In conclusion, shock delivery is most likely a surrogate parameter, reflecting higher all-cause mortality based on progressive deterioration of the underlying chronic heart failure with reduced ejection fraction.
1 - Death and damage caused by multiple direct current shocks: studies in an animal model. Wilson CM, Allen JD, Bridges JB, Adgey AA. Eur Heart J. 1988;9(11):1257-65.2 - Effect of ventricular shock strength on cardiac hemodynamics. Tokano T, Bach D, Chang J, Davis J, Souza JJ, Zivin A, Knight BP, Goyal R, Man KC, Morady F, Strickberger SA. J Cardiovasc Electrophysiol. 1998;9(8):791-7.3 - Spatial distribution and extent of electroporation by strong internal shock in intact structurally normal and chronically infarcted rabbit hearts. Kim SC, Vasanji A, Efimov IR, Cheng Y. J Cardiovasc Electrophysiol. 2008;19(10):1080-9.4 - Atria are more susceptible to electroporation than ventricles: implications for atrial stunning, shock-induced arrhythmia and defibrillation failure. Fedorov VV, Kostecki G, Hemphill M, Efimov IR. Heart Rhythm. 2008;5(4):593-604.5 - Myocardial injury after electrical therapy for cardiac arrhythmias assessed by troponin-T release. Runsiö M, Kallner A, Källner G, Rosenqvist M, Bergfeldt L. Am J Cardiol. 1997;79(9):1241-5.6 - Hemodynamic deterioration during ICD implant: predictors of high-risk patients. Steinbeck G, Dorwarth U, Mattke S, Hoffmann E, Markewitz A, Kaulbach H, Tassani P. Am Heart J. 1994;127(4 Pt 2):1064-7.7 - Prognostic importance of defibrillator shocks in patients with heart failure. Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, Reddy RK, Marchlinski FE, Yee R, Guarnieri T, Talajic M, Wilber DJ, Fishbein DP, Packer DL, Mark DB, Lee KL, Bardy GH. N Engl J Med. 2008;359(10):1009-17.8 - Differences in effects of electrical therapy type for ventricular arrhythmias on mortality in ICD patients. Sweeney MO, Sherfesee L, DeGroot PJ, Wathen MS, Wilkoff BL. Heart Rhythm. 2010;7(3):353-60.9 - Impact of shocks on mortality n patients with ischemic or dilated cardiomyopathy and defibrillators implanted for primary prevention. Streitner F, Herrmann T, Kuschyk J, Lang S, Doesch C, Papavassiliu T, Streitner I, Veltmann C, Haghi D, Borggrefe M. PLoS One. 2013;8(5):e63911.10 - Survival afters hock therapy in implantable cardioverter-defibrillator and cardiac resynchronisation therapy-defibrillator recipients according to rhythm shocked. Powell BD, Saxon LA, Boehmer JP, Day JD, Gilliam FR 3rd, Heidenreich PA, Jones PW, Rousseau MJ, Hayes DL. The ALTITUDE survival by rhythm study. J Am Coll Cardiol. 2013;62(18):1674-9.
11 - Impact of accelerated ventricular tachyarrhythmias on mortality in patients with ICD therapy. Schukro C, Leitner L, Siebermair J, Pezawas T, Stix G, Kastner J, Schmidinger H. Int J Cardiol. 2013;167(6):3006-10.12 - Empirical versus tested antitachycardia pacing in implantable cardioverter defibrillators: a prospective study including 200 patients. Schaumann A, von zur Mühlen F, Herse B, Gonska BD, Kreuzer H. Circulation 1998;97:66-74.13 - Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease. Wathen MS, Sweeney MO, DeGroot PJ, et al.; PainFREE Investigators. Circulation 2001;104:796-801.14 - Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial. Wathen MS, DeGroot PJ, Sweeney MO, et al.; PainFREE Rx II Investigators. Circulation 2004;110:2591-2596.15 - Optimizing implantable cardioverter-defibrillator treatment of rapid ventricular tachycardia: antitachycardia pacing therapy during charging. Schoels W, Steinhaus D, Johnson WB, et al.; EnTrust Clinical Study Investigators. Heart Rhythm 2007;4:879-885.16 - A randomized study to compare ramp versus burst antitachycardia pacing therapies to treat fast ventricular tachyarrhythmias in patients with ICD: the PITAGORA ICD trial. Gulizia MM, Piraino L, Scherillo M, et al.; PITAGORA ICD Study Investigators. Circ Arrhythm Electrophysiol 2009;2:146-153.17 - Transient local injury current in right ventricular electrogram after implantable cardioverter-defibrillator shock predicts heart failure progression. Tereshchenko LG, Faddis MN, Fetics BJ, Zelik KE, Efimov IR, Berger RD. J Am Coll Cardiol. 2009;54(9):822-8.
Christoph Schukro, MD, PhD, FESC. Medizinische Universität WienUniv.Klinik für Innere Medizin IIAbteilung für KardiologieAuthor's disclosures: None declared. Other resourcesThe subcutaneous defibrillator: who stands to benefit. Remote monitoring, described.
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved